Publication on the Mongolian gerbil brain provides scientific context for Bioxytran's Universal Oxygen Carrier research and tissue oxygenation assessment
BOSTON, June 3, 2025 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing investigational therapeutics for stroke, neurodegenerative diseases, viral infections, and other significant unmet medical needs, today announced the publication of The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States, authored by Bioxytran Science Advisor Professor Avraham Mayevsky and published by Springer.
The publication represents an important scientific resource for Bioxytran's ongoing research into oxygen transport, tissue oxygenation, ischemic stroke, and neurodegenerative disease. The research is particularly relevant to the Company's development of its Universal Oxygen Carrier (UOC) program and the use of the MDX Viewer as an analytical tool for evaluating changes in tissue oxygenation and brain metabolism.
The book is available in eBook and hardcover formats through Springer.
Bioxytran's UOC program is focused on developing an investigational oxygen transport technology designed to deliver oxygen to tissues affected by impaired blood flow.
The approach is particularly relevant to ischemic conditions such as stroke, where interruption of blood flow can deprive brain tissue of oxygen and contribute to cellular injury.
Research into the Mongolian gerbil brain provides a well-established experimental model for studying ischemia because of the animal's distinctive cerebral vascular characteristics. The model can allow researchers to examine changes in brain metabolism, mitochondrial function, vascular responses, and tissue oxygenation following reductions in blood flow.
Professor Mayevsky's publication brings together decades of research examining these biological processes and provides scientific context relevant to Bioxytran's ongoing oxygen therapeutic development.
The Mongolian gerbil has been widely used in experimental research involving cerebral ischemia because its cerebral circulation differs from that of many other laboratory animals.
In particular, the gerbil's limited collateral circulation can make reductions in cerebral blood flow more pronounced following vascular occlusion. This characteristic provides researchers with an experimental model for examining the metabolic and physiological consequences of ischemia.
The research compiled in Professor Mayevsky's book examines the relationship between mitochondrial function, cerebral blood flow, metabolism, and pathophysiological changes in the gerbil brain.
For Bioxytran, this research provides a framework for understanding how changes in oxygen availability can be observed and measured during ischemic conditions.
A key component of Bioxytran's oxygen transport research is the MDX Viewer, which the Company identifies as an FDA-cleared device capable of measuring tissue oxygenation.
The technology is being considered as an analytical method for evaluating how brain tissue responds to changes in oxygen availability during experimental studies.
In the context of the UOC program, the ability to monitor tissue oxygenation and metabolic responses could provide researchers with additional information when evaluating an investigational oxygen transport technology.
Rather than relying solely on conventional clinical endpoints, tissue-level measurements may provide insight into how oxygen availability changes within affected regions of the brain.
Ischemic stroke occurs when blood flow to part of the brain is interrupted, limiting the delivery of oxygen and nutrients to affected tissue.
The resulting oxygen deficit can disrupt cellular metabolism and mitochondrial function and, when sufficiently severe or prolonged, contribute to irreversible tissue injury.
Bioxytran's oxygen transport research is based on the premise that improving oxygen availability to compromised tissues could have therapeutic relevance in ischemic conditions.
The UOC program is therefore being investigated as a potential approach to oxygen delivery in situations where conventional circulation is impaired. Additional preclinical and clinical research will be required to determine whether this approach can translate into meaningful therapeutic benefits.
Bioxytran's oxygen therapeutics research also extends beyond acute ischemic stroke.
The Company is investigating the potential relevance of oxygen transport technologies to neurodegenerative diseases, including Alzheimer's disease, where changes in cerebral blood flow, metabolism, mitochondrial function, and tissue oxygenation have been the subject of extensive scientific research.
Professor Mayevsky's work provides a broader scientific foundation for examining these relationships and understanding how changes in brain physiology can be detected experimentally.
The Company intends to use these research insights as part of its continuing evaluation of oxygen-based therapeutic approaches.
The publication also supports the scientific framework surrounding Bioxytran's broader oxygen transport research, including its investigational candidate BXT-25.
BXT-25 is being developed as an oxygen therapeutic for conditions associated with impaired oxygen delivery, including potential applications in ischemic stroke, traumatic brain injury (TBI), dementia, and Alzheimer's disease.
The Company's broader strategy is to investigate whether oxygen transport technologies can improve oxygen availability at the tissue level during conditions in which normal blood flow or oxygen delivery has been compromised.
The UOC program represents an additional component of this research platform.
One of the challenges in developing therapies for ischemic and neurodegenerative diseases is determining how an intervention affects the underlying biological processes occurring within affected tissue.
Bioxytran's research strategy incorporates tissue oxygenation and metabolic measurements to investigate these responses.
The combination of the Mongolian gerbil model, Professor Mayevsky's research, and the MDX Viewer provides a framework for studying changes associated with cerebral ischemia and oxygen delivery.
These tools may help Bioxytran evaluate the biological effects of its investigational oxygen transport technologies as the Company advances its preclinical and clinical development programs.
The publication of Professor Mayevsky's book does not itself establish the safety or efficacy of Bioxytran's UOC or BXT-25 programs. Instead, it provides scientific and experimental context for the Company's continuing research.
Bioxytran expects to build on this scientific foundation as it evaluates oxygen transport, tissue oxygenation, and metabolic responses in its development programs.
Further preclinical studies, clinical investigations, and regulatory review will be necessary to determine the safety, efficacy, and potential clinical applications of these investigational technologies.
The publication adds to Bioxytran's broader efforts to develop technologies addressing conditions associated with impaired oxygen delivery and tissue hypoxia.
By integrating research into cerebral metabolism, vascular function, mitochondrial activity, and tissue oxygenation, the Company is investigating new approaches to understanding and potentially addressing oxygen deprivation in the brain.
The work is particularly relevant to Bioxytran's long-term development strategy for ischemic stroke and neurodegenerative disease, where tissue oxygenation represents an important component of disease biology.
Bioxytran will continue advancing its research into oxygen transport and tissue oxygenation, including development activities associated with its UOC program and BXT-25.
The Company will evaluate scientific data generated through its research programs to guide future development and regulatory planning.
Additional studies will be required to establish whether the Company's investigational oxygen transport technologies can safely and effectively improve tissue oxygenation and provide clinical benefit in stroke, neurodegenerative disease, or other conditions.
The Mongolian Gerbil Brain: Mitochondrial Function, Vasculature, and Pathophysiological States examines the relationship between brain metabolism, mitochondrial function, cerebral vasculature, and pathological states using the Mongolian gerbil as an experimental model.
The publication represents the culmination of decades of research by Professor Avraham Mayevsky and provides a comprehensive scientific reference for researchers studying cerebral ischemia, brain metabolism, and related pathophysiological processes.
The book is published by Springer and is available in eBook and hardcover formats.
Bioxytran, Inc. is a clinical-stage biotechnology company developing investigational therapeutics designed to address significant unmet medical needs. The Company's research platform combines glycovirology, carbohydrate drug design, galectin biology, and oxygen therapeutics.
Bioxytran's lead investigational antiviral candidate, ProLectin-M, is an orally administered galectin antagonist being developed for viral diseases. The Company is also advancing oxygen transport research through its Universal Oxygen Carrier (UOC) program and BXT-25, with research focused on conditions associated with impaired oxygen delivery, tissue hypoxia, ischemic stroke, traumatic brain injury, dementia, and Alzheimer's disease.
For more information, visit www.bioxytraninc.com.
This news release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning Bioxytran's oxygen therapeutics programs, Universal Oxygen Carrier technology, BXT-25, the potential applications of tissue oxygenation measurements, future research, clinical development, regulatory activities, and potential therapeutic benefits. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
Factors that may affect future results include preclinical and clinical study outcomes, regulatory decisions, development timelines, manufacturing requirements, funding availability, intellectual property considerations, strategic partnerships, and other risks described in Bioxytran's filings with the U.S. Securities and Exchange Commission. Bioxytran undertakes no obligation to update forward-looking statements except as required by applicable law.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
